Relevant Biomarkers in Medical Practices: An Analysis of the Needs Addressed by an International Survey.
Fiche publication
Date publication
janvier 2022
Journal
Journal of personalized medicine
Auteurs
Membres identifiés du Cancéropôle Est :
Dr GOETZ Christophe
Tous les auteurs :
Abensur Vuillaume L, Leichle T, Le Borgne P, Grajoszex M, Goetz C, Voss PL, Ougazzaden A, Salvestrini JP, d'Ortho MP
Lien Pubmed
Résumé
(1) Backround: Technological advances should foster gains in physicians' efficiency. For example, a reduction of the medical decision time can be enabled by faster biological tests. The main objective of this study was to collect responses from an international panel of physicians on their needs for biomarkers and also to convey the improvement in the outcome to be made possible by the potential development of fast diagnostic tests for these biomarkers. (2) Methods: we distributed a questionnaire on the Internet to physicians. (3) Results: 508 physicians participated in this survey. The mean age was 38 years. General practice and emergency medicine were heavily represented, with 95% CIs of 44% (39.78, 48.41) and 32% (27.84, 35.94)), respectively. The two most represented countries were France (95% CI: 74% (70.20, 77.83)) and the USA (95% CI: 11% (8.65, 14.18)). Ninety-eight percentages of the physicians thought that obtaining cited biomarkers more quickly would be beneficial to their practice and to patient's care. The main biomarkers of interest identified by our panel were troponin (95% CI: 51% (46.24, 54.94)), C-reactive protein (95% CI: 42% (38.03, 46.62)), D-dimer (95% CI: 29% (24.80, 32.68)), and brain natriuretic peptide (95% CI: 13% (10.25, 16.13)). (4) Conclusions: Our study highlights the real technological need for fast biomarker results, which could be provided by biosensors. The relevance of some answers such as troponin is questionable.
Mots clés
biomarkers, biosensors, emergency overcrowding
Référence
J Pers Med. 2022 Jan 14;12(1):